AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27367949 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole vs placebo (historical comparison)
Number of subjects: 30
Study 27369069 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat condition (unpredictable electrical shock)
Number of subjects: 0
Study 27369069 — intervention group
Group type: COMPARATOR
Intervention: Safe condition (no shock)
Number of subjects: 0
Study 27369488 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized diet-modification and weight-modification program
Number of subjects: 0
Study 27369488 — intervention group
Group type: COMPARATOR
Intervention: Standard informational health website
Number of subjects: 0
Study 27369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Jødal and Brøchner-Mortensen (JBM) formula from 2009 with sampling at 2 and 5 hours
Number of subjects: 96
Study 27369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Brøchner-Mortensen method from 1972 with early BSA normalization
Number of subjects: 96
Study 27369694 — intervention group
Group type: EXPERIMENTAL
Intervention: Other formulas with early BSA normalization
Number of subjects: 96
Study 27369803 — intervention group
Group type: EXPERIMENTAL
Intervention: CoreValve THV with adherence to sizing algorithm
Number of subjects: 1023
Study 27369803 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DARs
Number of subjects: 1023
Study 27369803 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to sizing algorithm
Number of subjects: 1023
Study 27370649 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted fortification of human milk (adding macronutrients to achieve 4.4 g fat, 8.8 g carbohydrates, and 3 g protein per 100 ml)
Number of subjects: 10
Study 27370649 — intervention group
Group type: COMPARATOR
Intervention: Standard fortified human milk
Number of subjects: 10
Study 27370913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oritavancin
Number of subjects: 1910
Study 27370913 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose vancomycin
Number of subjects: 1910
Study 27371698 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily, days 1-21 of a 28-day cycle
Number of subjects: 33
Study 27373141 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of Rotarix™ (GlaxoSmithKline, Belgium)
Number of subjects: 12511
Study 27373141 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized formulation of Rotarix™
Number of subjects: 12511
Study 27373595 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib
Number of subjects: 14042
Study 27373595 — intervention group
Group type: COMPARATOR
Intervention: Other DTaP-containing vaccines
Number of subjects: 14042
Study 27373745 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Adaptation Cohort (MAC)
Number of subjects: 32
Study 27373745 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise Cohort (TEC)
Number of subjects: 32
Study 27374464 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus R-CHOP-21 (intravenous rituximab 375 mg/m(2), intravenous cyclophosphamide 750 mg/m(2), intravenous doxorubicin 50 mg/m(2), intravenous vincristine 1·4 mg/m(2) [maximum 2·0 mg], oral prednisone 100 mg/m(2) on days 1-5 of the cycle) for six cycles.
Number of subjects: 24
Study 27374464 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day plus R-CHOP-21
Number of subjects: 24
Study 27374466 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells after chemotherapy
Number of subjects: 29
Study 27374466 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of non-HLA-matched ex-vivo expanded cord blood progenitor cells
Number of subjects: 29
Study 27374829 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum vitamin D (25(OH)D) levels categorized as ≤20 ng/mL
Number of subjects: 310
Study 27374829 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model based on supplement intake, nutritional status, race, and estimated creatinine clearance (eCCr)
Number of subjects: 310
Study 27374829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status and adequate supplementation
Number of subjects: 310
Study 27375040 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-hRPE65v2 (1.5 × 10(11) vector genomes) subretinally injected into the contralateral eye
Number of subjects: 11
Study 27376543 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake (VO2 max)
Number of subjects: 136
Study 27376543 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic flexibility (ΔRQ)
Number of subjects: 136
Study 27377575 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 774
Study 27377575 — intervention group
Group type: COMPARATOR
Intervention: Low-SNOT CRS patients
Number of subjects: 774
Study 27377575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-SNOT CRS patients undergoing ESS
Number of subjects: 774
Study 27377635 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 106
Study 27377635 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 106
Study 27378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Low platelet reactivity (LTA tertile 1)
Number of subjects: 0
Study 27378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin dose ≥300 mg
Number of subjects: 0
Study 27378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass time
Number of subjects: 0
Study 27378554 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroSCORE
Number of subjects: 0
Study 27378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertile distribution of platelet reactivity
Number of subjects: 0
Study 27378875 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 46
Study 27378875 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 46
Study 27379556 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 123
Study 27379556 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 123
Study 27379556 — intervention group
Group type: COMPARATOR
Intervention: High PTH levels
Number of subjects: 123
Study 27379560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (BTZ) 1.3 mg/m of body surface area
Number of subjects: 10
Study 27379610 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated SeQuent Please drug-coated balloon (DCB)
Number of subjects: 46
Study 27379610 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided DCB-only PCI
Number of subjects: 46
Study 27379610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinuation after 4 weeks
Number of subjects: 46
Study 27379823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole (target dose: 3 mg/d)
Number of subjects: 54
Study 27379966 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS) with ingestible sensor and wearable sensor
Number of subjects: 59
Study 27379966 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Medicine System (DMS)
Number of subjects: 59
Study 27381858 — intervention group
Group type: COMPARATOR
Intervention: Typical presentation and no-comorbidities
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical presentation and comorbidities
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical presentation and no-comorbidities
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical presentation and comorbidities
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical presentation
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 11458
Study 27381858 — intervention group
Group type: EXPERIMENTAL
Intervention: Underuse of invasive procedures
Number of subjects: 11458
Study 27381904 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 mg with weekly dexamethasone 20 mg (cohort 3)
Number of subjects: 27
Study 27382096 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, gemcitabine, and vinorelbine (BeGEV)
Number of subjects: 59
Study 27382289 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilazodone 20-40 mg/day
Number of subjects: 1373
Study 27382289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1373
Study 27383993 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and active MT
Number of subjects: 132
Study 27383993 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and active MT
Number of subjects: 132
Study 27383993 — intervention group
Group type: COMPARATOR
Intervention: Active tDCS and sham MT
Number of subjects: 132
Study 27383993 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and sham MT
Number of subjects: 132
Study 27384242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Care Infection Score (ICIS)
Number of subjects: 301
Study 27384242 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 301
Study 27384242 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 301
Study 27384417 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0T-MRU
Number of subjects: 20
Study 27384417 — intervention group
Group type: COMPARATOR
Intervention: CTU
Number of subjects: 20
Study 27385608 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric ketogenic diet (KD)
Number of subjects: 17
Study 27385608 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate baseline diet (BD)
Number of subjects: 17
Study 27385614 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominantly nighttime feeding (pNT)
Number of subjects: 349
Study 27385614 — intervention group
Group type: COMPARATOR
Intervention: Predominantly daytime feeding (pDT)
Number of subjects: 349
Study 27385761 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary acid load (measured by potential renal acid load, PRAL)
Number of subjects: 81797
Study 27385761 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-base balanced diet
Number of subjects: 81797
Study 27385763 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein, lower-carbohydrate or -fat diet during pregnancy
Number of subjects: 320
Study 27385763 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher maternal intake of animal protein
Number of subjects: 320
Study 27385763 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal macronutrient intake
Number of subjects: 320
Study 27386049 — intervention group
Group type: EXPERIMENTAL
Intervention: One weekly low-level laser therapy treatment for six weeks
Number of subjects: 54
Study 27386758 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized electronic case report forms completed by trained study coordinators, including demographic factors, medical history, processes of inpatient care, and baseline interview on time delays to hospital admission.
Number of subjects: 14326
Study 27386758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective individual patient follow-up focusing on patient health (symptoms) and vital status.
Number of subjects: 14326
Study 27386758 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood sampling for genetic data obtained at hospital discharge.
Number of subjects: 14326
Study 27386758 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent enrollment of patients from some European Union founding members.
Number of subjects: 14326
Study 27386769 — intervention group
Group type: EXPERIMENTAL
Intervention: Val122Ile mutation
Number of subjects: 390
Study 27386769 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type ATTR
Number of subjects: 390
Study 27386769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall U.S. ATTR patients
Number of subjects: 390
Study 27386769 — intervention group
Group type: COMPARATOR
Intervention: U.S. ATTR patients
Number of subjects: 390
Study 27387422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygiene-based intervention for skin and soft-tissue infection prevention; details on dosage and duration not available.
Number of subjects: 0
Study 27387422 — intervention group
Group type: COMPARATOR
Intervention: Control group; details on intervention not available.
Number of subjects: 0
Study 27387446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertumaxomab (ertu) administered intravenously in 2 cycles with ascending doses (10-500 μg) weekly for 28 days with a 21-day treatment-free interval.
Number of subjects: 14
Study 27387922 — intervention group
Group type: EXPERIMENTAL
Intervention: Full set of three satiety hormones
Number of subjects: 0
Study 27387922 — intervention group
Group type: EXPERIMENTAL
Intervention: Set of two satiety hormones
Number of subjects: 0
Study 27387922 — intervention group
Group type: EXPERIMENTAL
Intervention: Set of one satiety hormone
Number of subjects: 0
Study 27387922 — intervention group
Group type: EXPERIMENTAL
Intervention: High satiating food types
Number of subjects: 0
Study 27387922 — intervention group
Group type: EXPERIMENTAL
Intervention: Less satiating food types
Number of subjects: 0
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with paid or casual partners in the past month
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perceived risk of getting STI/HIV
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom negotiation
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use for vaginal sex
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of sexual partners
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural interventions on condom negotiation skills and condom use
Number of subjects: 220
Study 27388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical interventions on STI/HIV testing and treatment
Number of subjects: 220
Study 27388474 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, high-protein (HFHP) meals with adaptive model-predictive insulin bolus
Number of subjects: 10
Study 27388474 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose adjustments for HFHP meals
Number of subjects: 10
Study 27388474 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, low-protein (LFLP) meals
Number of subjects: 10
Study 27388490 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical dispatchers recognizing acute stroke during emergency calls
Number of subjects: 2653
Study 27388490 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency calls during daytime
Number of subjects: 2653
Study 27388490 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis of TIA vs. intracerebral hemorrhage (ICH)
Number of subjects: 2653
Study 27388610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-D) in non-obese patients
Number of subjects: 1278
Study 27388610 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT-D) in obese patients
Number of subjects: 1278
Study 27388672 — intervention group
Group type: EXPERIMENTAL
Intervention: TREAT subjects (polyarticular JIA)
Number of subjects: 0
Study 27388672 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 27389402 — intervention group
Group type: EXPERIMENTAL
Intervention: NGF-ECB implants
Number of subjects: 4
Study 27389410 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Department Mental Health Clinical Pathway (EDMHCP)
Number of subjects: 0
Study 27390310 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120
Study 27390310 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSPRI (European League Against Rheumatism Sjögren's Syndrome Patient Reported Index)
Number of subjects: 120
Study 27390310 — intervention group
Group type: EXPERIMENTAL
Intervention: ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index)
Number of subjects: 120
Study 27390845 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic CTCs in follow-up samples
Number of subjects: 52
Study 27390845 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC clusters in follow-up samples
Number of subjects: 52
Study 27390845 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-CTCs presence
Number of subjects: 52
Study 27390845 — intervention group
Group type: EXPERIMENTAL
Intervention: Apoptotic CTCs or clusters at any time-point
Number of subjects: 52
Study 27390845 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC clusters at baseline
Number of subjects: 52
Study 27390847 — intervention group
Group type: EXPERIMENTAL
Intervention: AVDCX regimen (cisplatin 25-35 mg/m2, docetaxel 25-35 mg/m2, capecitabine 1,600 mg/m2, bevacizumab 7.5 mg/kg)
Number of subjects: 22
Study 27390847 — intervention group
Group type: EXPERIMENTAL
Intervention: AVDCX regimen at maximum tolerated dose (MTD)
Number of subjects: 22
Study 27390847 — intervention group
Group type: EXPERIMENTAL
Intervention: AVDCX regimen
Number of subjects: 22
Study 27391216 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 0
Study 27391902 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-free fluid with magnesium concentration of 1.50 mmol/l
Number of subjects: 45
Study 27391902 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnesium containing fluid (3,000 ml/h)
Number of subjects: 45
Study 27391902 — intervention group
Group type: COMPARATOR
Intervention: Ordinary dialysis fluid
Number of subjects: 45
Study 27391902 — intervention group
Group type: COMPARATOR
Intervention: Calcium-free fluid with magnesium concentration of 0.75 mmol/l
Number of subjects: 45
Study 27392380 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Classroom Instruction (ACI)
Number of subjects: 32
Study 27392380 — intervention group
Group type: COMPARATOR
Intervention: Normal Classroom Instruction (NCI)
Number of subjects: 32
Study 27392483 — intervention group
Group type: EXPERIMENTAL
Intervention: MK8245 (liver-specific SCD-1 inhibitor)
Number of subjects: 0
Study 27392483 — intervention group
Group type: COMPARATOR
Intervention: Direct anti-viral agents and interferon-alpha therapy
Number of subjects: 0
Study 27394384 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-continuous glucose monitoring technology
Number of subjects: 24
Study 27394384 — intervention group
Group type: COMPARATOR
Intervention: Gold standard Yellow Springs Instrument (YSI)
Number of subjects: 24
Study 27395070 — intervention group
Group type: EXPERIMENTAL
Intervention: ST elevation acute coronary syndrome (STE-ACS)
Number of subjects: 5140
Study 27395070 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ST elevation acute coronary syndrome (NSTE-ACS)
Number of subjects: 5140
Study 27395070 — intervention group
Group type: COMPARATOR
Intervention: Older patients (age > 65)
Number of subjects: 5140
Study 27395381 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH-protocols
Number of subjects: 18
Study 27395381 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline recommendations in protocols
Number of subjects: 18
Study 27396777 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable intravascular delivery system for treprostinil infusion
Number of subjects: 60
Study 27398025 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m(2) on days 1 and 8
Number of subjects: 1102
Study 27398025 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine 1250 mg/m(2) on days 1-14
Number of subjects: 1102
Study 27398025 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1102
Study 27398272 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet
Number of subjects: 15
Study 27398407 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable artificial kidney
Number of subjects: 10
Study 27399966 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese population (1,659 cases)
Number of subjects: 1659
Study 27399966 — intervention group
Group type: EXPERIMENTAL
Intervention: European population (4,036 cases)
Number of subjects: 1659
Study 27399966 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication study in Chinese (3,043 cases)
Number of subjects: 1659
Study 27399966 — intervention group
Group type: EXPERIMENTAL
Intervention: Replication study in European (2,643 cases)
Number of subjects: 1659
Study 27399966 — intervention group
Group type: COMPARATOR
Intervention: Comparison of risk allele frequencies and genetic risk scores
Number of subjects: 1659
Study 27399982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyspecific immunoglobulin G (IVIG)
Number of subjects: 0
Study 27399982 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study 27399982 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 0
Study 27400222 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks thereafter up to 360 weeks
Number of subjects: 310
Study 27400222 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 310
Study 27400814 — intervention group
Group type: EXPERIMENTAL
Intervention: aortic pulse wave velocity (aPWV)
Number of subjects: 627
Study 27400896 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of pravastatin, zoledronic acid, and lonafarnib
Number of subjects: 37
Study 27400898 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter aortic valve replacement
Number of subjects: 583
Study 27400907 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exacerbations
Number of subjects: 409
Study 27400907 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-physician chart review
Number of subjects: 409
Study 27400907 — intervention group
Group type: COMPARATOR
Intervention: Central adjudication by a committee (reference standard)
Number of subjects: 409
Study 27401348 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis Public-Private Partnership Programme (HD-PPP)
Number of subjects: 0